ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

ClinicalTrials.gov ID: NCT02408549

Public ClinicalTrials.gov record NCT02408549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy

Study identification

NCT ID
NCT02408549
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Enrollment
239 participants

Conditions and interventions

Conditions

Interventions

  • Lacosamide Oral Solution Drug
  • Lacosamide Tablet Drug

Drug

Eligibility (public fields only)

Age range
4 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2, 2015
Primary completion
Mar 29, 2023
Completion
Mar 29, 2023
Last update posted
Dec 13, 2023

2015 – 2023

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
EP0012 5 Little Rock Arkansas 72205
EP0012 8 Santa Monica California 90404
Ep0012 31 Colorado Springs Colorado 80907
Ep0012 42 Loxahatchee Groves Florida 33470
Ep0012 13 Panama City Florida 32405
EP0012 2 Port Charlotte Florida 33952
Ep0012 15 Boise Idaho 83702
Ep0012 21 Peoria Illinois 61637
Ep0012 25 Golden Valley Minnesota 55422
Ep0012 43 New York New York 10016
Ep0012 53 Austin Texas 78758
Ep0012 50 Greenville Texas 75401
Ep0012 34 Houston Texas 77005
Ep0012 38 San Antonio Texas 78229
Ep0012 27 Renton Washington 98057
Ep0012 23 Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02408549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 13, 2023 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02408549 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →